3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Cytarabine
25
Cyclophosphamide
23
venetoclax
16
Methotrexate
15
Daunorubicin
14
Dexamethasone
13
Vincristine
11
Etoposide
11
Azacitidine
10
Idarubicin
9
Decitabine
9
Busulfan
9
fludarabine
8
Radiotherapy
8
Prednisone
8
Stem Cell Transplantation
7
Mercaptopurine
7
Doxorubicin
7
Asparaginase
7
pegaspargase
6
fludarabine phosphate
6
blinatumomab
6
Granulocyte Colony-Stimulating Factor
6
Gemtuzumab
6
Filgrastim
6
Thiotepa
5
Methylprednisolone
5
Dasatinib
5
Whole-Body Irradiation
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Clavulanic Acid
×
Other hematologic neoplasm
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled